Cargando…

Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates

BACKGROUND: Antibiotic resistance mediated by the production of extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases is posing a serious threat in the management of the infections caused by Gram-negative pathogens. The aim of this study was to determine the prevalence of two AmpC β-lactamase...

Descripción completa

Detalles Bibliográficos
Autores principales: Aryal, Subhas Chandra, Upreti, Milan Kumar, Sah, Anil Kumar, Ansari, Meharaj, Nepal, Krishus, Dhungel, Binod, Adhikari, Nabaraj, Lekhak, Binod, Rijal, Komal Raj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699442/
https://www.ncbi.nlm.nih.gov/pubmed/33262619
http://dx.doi.org/10.2147/IDR.S284751
_version_ 1783616049751523328
author Aryal, Subhas Chandra
Upreti, Milan Kumar
Sah, Anil Kumar
Ansari, Meharaj
Nepal, Krishus
Dhungel, Binod
Adhikari, Nabaraj
Lekhak, Binod
Rijal, Komal Raj
author_facet Aryal, Subhas Chandra
Upreti, Milan Kumar
Sah, Anil Kumar
Ansari, Meharaj
Nepal, Krishus
Dhungel, Binod
Adhikari, Nabaraj
Lekhak, Binod
Rijal, Komal Raj
author_sort Aryal, Subhas Chandra
collection PubMed
description BACKGROUND: Antibiotic resistance mediated by the production of extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases is posing a serious threat in the management of the infections caused by Gram-negative pathogens. The aim of this study was to determine the prevalence of two AmpC β-lactamases genes, bla(CITM) and bla(DHAM), in Gram-negative bacterial isolates. MATERIALS AND METHODS: A total of 1151 clinical samples were obtained and processed at the microbiology laboratory of Annapurna Neurological Institute and Allied Science, Kathmandu between June 2017 and January 2018. Gram-negative isolates thus obtained were tested for antimicrobial susceptibility testing (AST) using Kirby–Bauer disk diffusion method. AmpC β-lactamase production was detected by disk approximation method using phenylboronic acid (PBA). Confirmed AmpC β-lactamase producers were further screened for bla(CITM) and bla(DHAM) genes by conventional polymerase chain reaction (PCR). RESULTS: Out of 1151 clinical specimens, 22% (253/1152) had bacterial growth. Of the total isolates, 89.3% (226/253) were Gram-negatives, with E. coli as the most predominant species (n=72) followed by Pseudomonas aeruginosa (n=41). In the AST, 46.9% (106/226) of the Gram-negative isolates were multidrug resistant (MDR). In disk diffusion test, 113 (50%) isolates showed resistance against cefoxitin, among which 91 isolates (83 by disk test and Boronic acid test, 8 by Boronic test only) were confirmed as AmpC β-lactamase-producers. In PCR assay, 90.1% (82/91) and 87.9% (80/91) of the isolates tested positive for production of bla(CITM) and bla(DHAM) genes, respectively. CONCLUSIONS: High prevalence of AmpC β-lactamase-producers in our study is an alarming sign. This study recommends the use of modern diagnostic facilities in the clinical settings for early detection and management which can optimize the treatment therapies, curb the growth and spread of the drug-resistant pathogens.
format Online
Article
Text
id pubmed-7699442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-76994422020-11-30 Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates Aryal, Subhas Chandra Upreti, Milan Kumar Sah, Anil Kumar Ansari, Meharaj Nepal, Krishus Dhungel, Binod Adhikari, Nabaraj Lekhak, Binod Rijal, Komal Raj Infect Drug Resist Original Research BACKGROUND: Antibiotic resistance mediated by the production of extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases is posing a serious threat in the management of the infections caused by Gram-negative pathogens. The aim of this study was to determine the prevalence of two AmpC β-lactamases genes, bla(CITM) and bla(DHAM), in Gram-negative bacterial isolates. MATERIALS AND METHODS: A total of 1151 clinical samples were obtained and processed at the microbiology laboratory of Annapurna Neurological Institute and Allied Science, Kathmandu between June 2017 and January 2018. Gram-negative isolates thus obtained were tested for antimicrobial susceptibility testing (AST) using Kirby–Bauer disk diffusion method. AmpC β-lactamase production was detected by disk approximation method using phenylboronic acid (PBA). Confirmed AmpC β-lactamase producers were further screened for bla(CITM) and bla(DHAM) genes by conventional polymerase chain reaction (PCR). RESULTS: Out of 1151 clinical specimens, 22% (253/1152) had bacterial growth. Of the total isolates, 89.3% (226/253) were Gram-negatives, with E. coli as the most predominant species (n=72) followed by Pseudomonas aeruginosa (n=41). In the AST, 46.9% (106/226) of the Gram-negative isolates were multidrug resistant (MDR). In disk diffusion test, 113 (50%) isolates showed resistance against cefoxitin, among which 91 isolates (83 by disk test and Boronic acid test, 8 by Boronic test only) were confirmed as AmpC β-lactamase-producers. In PCR assay, 90.1% (82/91) and 87.9% (80/91) of the isolates tested positive for production of bla(CITM) and bla(DHAM) genes, respectively. CONCLUSIONS: High prevalence of AmpC β-lactamase-producers in our study is an alarming sign. This study recommends the use of modern diagnostic facilities in the clinical settings for early detection and management which can optimize the treatment therapies, curb the growth and spread of the drug-resistant pathogens. Dove 2020-11-24 /pmc/articles/PMC7699442/ /pubmed/33262619 http://dx.doi.org/10.2147/IDR.S284751 Text en © 2020 Aryal et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Aryal, Subhas Chandra
Upreti, Milan Kumar
Sah, Anil Kumar
Ansari, Meharaj
Nepal, Krishus
Dhungel, Binod
Adhikari, Nabaraj
Lekhak, Binod
Rijal, Komal Raj
Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates
title Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates
title_full Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates
title_fullStr Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates
title_full_unstemmed Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates
title_short Plasmid-Mediated AmpC β-Lactamase CITM and DHAM Genes Among Gram-Negative Clinical Isolates
title_sort plasmid-mediated ampc β-lactamase citm and dham genes among gram-negative clinical isolates
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699442/
https://www.ncbi.nlm.nih.gov/pubmed/33262619
http://dx.doi.org/10.2147/IDR.S284751
work_keys_str_mv AT aryalsubhaschandra plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT upretimilankumar plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT sahanilkumar plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT ansarimeharaj plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT nepalkrishus plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT dhungelbinod plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT adhikarinabaraj plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT lekhakbinod plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates
AT rijalkomalraj plasmidmediatedampcblactamasecitmanddhamgenesamonggramnegativeclinicalisolates